MUMBAI, India, April 25 -- Intellectual Property India has published a patent application (202517031938 A) filed by Astrazeneca Ab, Sodertalje, Sweden, on March 31, for 'combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases.'
Inventor(s) include Karlsson, Eva; Karlsson, Christer; and Hjartstam, Johan.
The application for the patent was published on April 25, under issue no. 17/2025.
According to the abstract released by the Intellectual Property India: "A pharmaceutical composition comprising: (a) one or more of a first pellet comprising i. a first core, and ii. a first coating on the first core, wherein the first coating comprises a mineralocorticoid receptor (MR) modulator...